ST Pharm announced the detailed Phase 1 clinical trial results of its tankyrase inhibitor anticancer drug, Basroparib (STP1002), during the European Society for Medical Oncology (ESMO). 

Basroparib is the first drug of its kind to complete human trials, showing promising safety and tolerability results in patients with advanced solid tumors.

In the trial, 25 patients (23 with colon cancer and 2 with renal cancer) were administered Basroparib across seven dose levels. 

Most side effects were mild, with only four cases of severe adverse reactions. Importantly, no significant bone loss was observed, and the drug showed potential anticancer activity, stabilizing the disease in four patients.

Moving forward, the recommended Phase 2 dosage is set at 360mg, with plans for combination trials with other anticancer therapies. 

ST Pharm intends to continue exploring Basroparib's potential through further clinical trials and potential licensing opportunities.